C1orf192 Inhibitors are a diverse set of chemical compounds that indirectly attenuate the functional activity of C1orf192 through various specific signaling pathways and cellular processes. Staurosporine, LY 294002, Rapamycin, PD 98059, SB 203580, U0126, and SP600125 serve as kinase inhibitors. For instance, Staurosporine broadly inhibits protein kinases potentially affecting C1orf192's phosphorylation status, while LY294002 specifically inhibits PI3K dampening the PI3K/Akt pathway which may be crucial for the stability or localization of C1orf192. Rapamycin, an mTOR inhibitor, and PD 98059, a MEK inhibitor, could interfere with the mTOR and MAPK/ERK pathways, respectively, pathways that might be critical for the functional expression of C1orf192. Similarly, SB 203580, U0126, and SP600125 target the p38 MAPK, MEK1/2, and JNK pathways, respectively, which may also play a role in modulating the activity of C1orf192 if it is indeed regulated by these pathways.
Further along the spectrum of C1orf192 inhibitors are MG-132, Cyclosporin A, 2-Deoxy-D-glucose, Chelerythrine, and W-7. MG-132 inhibits the proteasome, which could lead to the stabilization of proteins that negatively regulate C1orf192, thus reducing its activity. Cyclosporin A, by inhibiting calcineurin, could decrease the activity of NFAT or other calcineurin-dependent factors that may control C1orf192 activity. 2-Deoxy-D-glucose interferes with glycolysis and could affect C1orf192 if it relies on high-energy conditions or is regulated by energy-sensing pathways. Chelerythrine selectively inhibits PKC, which could reduce C1orf192 activity if PKC signaling is involved in its activation or stability. Lastly, W-7 antagonizes calmodulin, which could lead to the inhibition of C1orf192 if calmodulin-dependent signaling is part of its regulatory mechanism. Each of these inhibitors, through their targeted effects on specific cellular signaling pathways and processes, contribute to the collective potential to diminish the functional activity of C1orf192.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent, non-selective inhibitor of protein kinases. By inhibiting kinase activity, Staurosporine can indirectly diminish the phosphorylation state of proteins downstream of kinase signaling, which may include C1orf192. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3K. By blocking PI3K, LY 294002 dampens the PI3K/Akt pathway, potentially leading to reduced activity of proteins that are dependent on this pathway for stability or localization, such as C1orf192. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor which can reduce the activity of proteins involved in mTOR signaling. If C1orf192 activity or stability is linked to mTOR pathway signals, Rapamycin could lead to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which could reduce the activity of proteins downstream of MEK. If C1orf192 is regulated by the MAPK/ERK pathway, PD 98059 could indirectly reduce its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, potentially reducing the function of proteins regulated by p38 MAPK signaling. If C1orf192 is modulated by p38 MAPK, SB 203580 could lead to decreased C1orf192 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which may lead to the functional inhibition of proteins regulated by the JNK pathway. If JNK signaling influences C1orf192 activity, SP600125 could decrease its function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor which can stabilize proteins targeted for degradation. If C1orf192 is regulated by ubiquitin-mediated degradation, MG132 could indirectly decrease its functional activity by stabilizing negative regulators. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
An immunosuppressant that inhibits calcineurin. If C1orf192 is regulated by NFAT or other calcineurin-dependent factors, Cyclosporin A could reduce C1orf192 activity. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
An inhibitor of glycolysis which can affect energy metabolism. If C1orf192 requires high energy levels or is regulated by energy-sensing pathways, 2-Deoxy-D-glucose could diminish its function. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
A selective inhibitor of PKC. If C1orf192 is activated or stabilized by PKC signaling, Chelerythrine could lead to reduced C1orf192 activity. |